Navigation Links
1-year results of bronchial thermoplasty in refractory asthma
Date:2/11/2008

Sunnyvale, CA, February 11, 2008 Asthmatx, Inc., a medical device company that has developed a catheter-based procedure under investigation for the treatment of asthma, announced today the publication of data from the Research in Severe Asthma (RISA) Trial of bronchial thermoplasty in the American Journal of Respiratory and Critical Care Medicine (AJRCCM, 2007; 176:1185-1191). The publication reports that despite a transient increase in procedure related adverse events, patients experienced longer term improvement in pulmonary function, improved quality of life and asthma control, and a reduction in rescue medication use for patients treated with bronchial thermoplasty.

Bronchial thermoplasty is a non-drug treatment for asthma and is currently under clinical investigation. Bronchial thermoplasty is an investigational procedure in which precisely controlled thermal energy is delivered with a tiny catheter to targeted airway walls of patients with asthma. This procedure is intended to reduce muscle in the walls of airways, and thereby decrease the ability of airways to narrow in patients with symptomatic asthma.

The RISA Trial was a randomized trial conducted at a total of eight centers in three countries, and evaluated the safety and efficacy of bronchial thermoplasty in a total of 32 adult subjects, randomized 1:1 between the BT group and Control group with severe persistent asthma who were symptomatic despite taking regular asthma medications.

In this group of patients with severe asthma, an increase in respiratory-related symptoms was expected and observed during the period immediately following the procedure. Most occurred within one day of the procedure and resolved on average within a week. Following the treatment period, respiratory-related symptoms were similar between treatment groups.

Almost 6 months after the procedure, compared to the control group, patients who received bronchial thermoplasty showed clinically and statistically significant improvements in pulmonary function, quality of life and asthma control. In addition, patients in the treatment group used an average of 25 fewer puffs per week of rescue medication than those in the untreated Control group.

All patients then attempted to reduce their inhaled and/or oral corticosteroids (OCS) during a 14 week period. Fifty percent (50%) of bronchial thermoplasty treated patients were able to wean completely off their oral corticosteroids (OCS), compared to 14% of patients who did not receive the treatment. This improvement did not reach statistical significance; however the study was not powered to show statistical significance in medication changes.

One year following treatment, and after the period of medication reduction, patients who received the bronchial thermoplasty procedure continued to show clinically and statistically significant improvements in quality of life and asthma control, and used less rescue medication .

We found that, in this population of severe asthma patients, bronchial thermoplasty was associated with a short-term increase in asthma-related symptoms around the time of treatment but showed a potential for a longer-term improvement in rescue medication use, lung function, asthma control and quality of life, states Ian D. Pavord, MD and principle investigator of the study at the Glenfield General Hospital, University Hospitals of Leicester. These potential long term improvements make us hopeful that bronchial thermoplasty could some day be a viable new treatment option for these severe asthma patients.


'/>"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Asthmatx
Source:Eurekalert  

Related medicine news :

1. Less than 3 percent of UK 11-year-olds take enough exercise
2. Rural/Metro Announces Results for Fiscal 2008 Second Quarter
3. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
4. LCA-Vision Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Neurobiological Technologies Reports Second Quarter Financial Results
6. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST
7. Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results
8. Huntsman to Discuss Fourth Quarter and Full Year 2007 Results on Friday, February 22, 2008
9. Chindex International, Inc. Announces Results for the Quarter and Nine Months Ended December 31, 2007
10. Natural Alternatives International, Inc. Announces Second Quarter Results
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
1-year results of bronchial thermoplasty in refractory asthma
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: